Inhalation Drug Delivery News

31. Kindeva Drug Delivery Acquisition Of iPharma Labs Inc. Completed 6/16/2022

    This acquisition combines iPharma’s deep expertise and track record in inhalation formulation and development of liquid, dry powder, and propellant-based therapies with Kindeva’s global expertise in developing, commercializing, and manufacturing inhaled therapies.

32. Kindeva Drug Delivery Announces Collaboration With Synopsys 6/15/2022

    Kindeva Drug Delivery (Kindeva) has announced a collaboration with Synopsys, Inc. involving the implementation of Synopsys Simpleware™ automated software solutions to assist in creating a state-of-the-art system for accurately measuring Kindeva’s microstructured transdermal system (MTS) arrays.

33. Lonza Completes Dedicated Early Clinical Phase Development And Manufacturing Facility In Bend (OR) 6/1/2022

    Lonza has enhanced its offering for customers in the early phases of their clinical trials by adding a dedicated Early Phase Clinical Manufacturing facility at its Small Molecules site in Bend, Oregon.

34. Piramal Pharma Solutions New API Plant In Canada Goes Online; Initial Production Runs Successfully Completed 5/19/2022

    Piramal Pharma Limited's Pharma Solutions business, a leading Contract Development and Manufacturing Organization (CDMO), today announced that a new active pharmaceutical ingredient (API) plant at the company's site in Aurora, Ontario, has come online and successfully completed its initial production runs

35. Kindeva And BOL Pharma Using Low Global Warming Potential (GWP) Propellant In Development Of Inhaled Cannabinoid Products 5/11/2022

    Subject to all required regulatory approvals, the products under development are targeted to treat chronic neuropathic pain. If successful, this early-stage activity could lead to the long-term commercial supply of regulated inhaled cannabinoid products using low GWP propellants, leveraging Kindeva’s commercial manufacturing capabilities and BOL’s accumulated know-how and innovation in the field of medical cannabis.

36. Kindeva Drug Delivery To Acquire iPharma Labs Inc. 5/2/2022

    This acquisition will combine iPharma’s deep expertise and track record in inhalation formulation and development of liquid, dry powder, and propellant-based therapies with Kindeva’s global expertise in developing, commercializing, and manufacturing inhaled therapies.

37. Virpax Pharmaceuticals Selects Kindeva Drug Delivery As Development Partner For Diclofenac pMDI Commercialization 4/27/2022

    Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) and Kindeva Drug Delivery will work together to advance the clinical program of the Virpax-developed Diclofenac topical spray film (Epoladerm™) in the United States.

38. Rokote Laboratories Selects Exothera For GMP Manufacturing Of Its Second-Generation Coronavirus Vaccine FINCoVac 2.0. 3/31/2022

    Rokote Laboratories Finland Ltd., a vaccine development company focussing on a second-generation COVID-19 vaccine, and Exothera S.A. will collaborate to bring the intranasal coronavirus vaccine FINCoVac 2.0 to clinical Phase I/II trials

39. BiondVax Signs Definitive Collaboration Agreement For The Development Of A Pipeline Of Innovative Nanosized Antibody (NanoAb) Therapies 3/25/2022

    BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, today announced the signing of definitive agreements with the Max Planck Society, the parent organization of the Max Planck Institute for Multidisciplinary Sciences (MPI), and the University Medical Center Göttingen (UMG), both in Germany, to enter into a strategic collaboration for the development of innovative nanosized antibodies (NanoAbs)

40. Viatris Inc. Announces Receipt Of The First FDA Approval For Generic Version Of Symbicort® Inhalation Aerosol, Breyna™ (Budesonide And Formoterol Fumarate Dihydrate Inhalation Aerosol), In Partnership With Kindeva 3/16/2022

    Viatris Inc. and Kindeva Drug Delivery announced that, Mylan Pharmaceuticals Inc., a Viatris subsidiary, has received approval from the U.S. FDA for its Abbreviated New Drug Application (ANDA) for Breyna^TM (Budesonide and Formoterol Fumarate Dihydrate Inhalation Aerosol), the first approved generic version of AstraZeneca’s Symbicort^®.